This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck
Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV
by Zacks Equity Research
J&J (JNJ) and Bristol-Myers (BMY) kick off earnings for pharma sector. Lilly (LLY) and AbbVie (ABBV) announce failure of late-stage studies.
Merck KGaA Gives Vertex Rights to Two Gene-Editing Compounds
by Zacks Equity Research
Merck KGaA (MKGAF) inks an exclusive licensing agreement with Vertex for two DNA-dependent protein kinase inhibitors in the field of gene editing for six specific genetic disease indications.
What's Behind the Biotech ETF Rally to Start 2019?
by Sanghamitra Saha
Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.
Bristol-Myers (BMY) Beats Q4 Earnings, Withdraws Opdivo sBLA
by Zacks Equity Research
Bristol-Myers (BMY) beats earnings estimates in the fourth quarter but misses sales expectation by a slight margin. Eliquis and Opdivo continue to record solid sales.
The Zacks Analyst Blog Highlights: Archer Daniels Midland, Molina Healthcare, Eli Lilly, Spark Energy and Lamb Weston
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Archer Daniels Midland, Molina Healthcare, Eli Lilly, Spark Energy and Lamb Weston
Sanofi's (SNY) Influenza Vaccine Gets FDA Approval for Kids
by Zacks Equity Research
Sanofi's (SNY) influenza vaccine, Fluzone Quadrivalent (0.5mL dose), gains an FDA nod for treating children in six to 35-month age group.
5 Best Biotech Bets Likely to Outperform Estimates in Q4
by Zacks Equity Research
Let us take a look at five promising biotech stocks for the fourth quarter of 2018.
6 Stocks to Prepare for a Global Economic Slowdown
by Swarup Gupta
A slowdown in Europe and the ongoing trade conflicts have been cited as the major reasons for the IMF's projection cuts.
J&J's (JNJ) Q4 Earnings Beat, 2019 Sales Forecast Soft
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the fourth quarter of 2018, leading to an increase in shares in pre-market trading. 2019 sales guidance falls short of expectations.
Company News For Jan 22, 2019
by Zacks Equity Research
Companies In The News Are: TIF,LLY,KSU,JBHT
Lilly Stops Lartruvo Promotion as Confirmatory Study Fails
by Zacks Equity Research
Eli Lilly's (LLY) Lartruvo combo is unable to demonstrate the clinical benefit for the primary endpoint of OS rate in a phase III study related to treating patients with metastatic soft tissue sarcoma.
Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY
by Zacks Equity Research
Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.
Here is Why Growth Investors Should Buy Lilly (LLY) Now
by Zacks Equity Research
Lilly (LLY) possesses solid growth attributes, which could help it handily outperform the market.
Pacira's Study on Exparel Label Expansion Meets Endpoints
by Madhu Goel
Pacira's (PCRX) phase IV study of its lead drug Exparel in patients undergoing Cesarean section achieves primary endpoint.
Ligand (LGND) Takes a Hit on Citron's Negative Research Report
by Zacks Equity Research
Ligand (LGND) plunges as short-seller Citron Research questions the company's business prospects.
Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings
by Zacks Equity Research
Shares of Kitov Pharma (KTOV) soar about 169% as the company's anti-cancer candidate, NT219 shows positive results.
Intrexon Signs Licensing Agreement with Next Green Wave
by Zacks Equity Research
Intrexon (XON) partners with Next Green Wave Holdings to utilize Intrexon's Botticelli next-generation plant propagation platform.
6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019
by Zacks Equity Research
Here are five reasons which investors may consider while investing in Lilly's (LLY) stock.
Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer
by Zacks Equity Research
Bristol-Myers (BMY) gets EU approval for the immuno-oncology combination of Opdivo and low-dose Yervoy for the first-line treatment of patients with intermediate- and poor-risk advanced RCC.
Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $114.68 in the latest trading session, marking a -1.29% move from the prior day.
5 Reasons Why Investors Should Buy Novo Nordisk (NVO) in 2019
by Zacks Equity Research
Novo Nordisk (NVO) has a strong presence in the Diabetes care market and its top line is driven by strong performance of products like Victoza.
Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why
by Zacks Equity Research
Puma Biotech's (PBYI) only marketed drug, Nerlynx, is suffering low sales due to higher patient discontinuations.
Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet
by Zacks Equity Research
Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.
4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019
by Kinjel Shah
Here we present four therapeutic areas whose pipeline developments are expected to garner a lot of interest in 2019.